Long COVID Immune Profiling
Long COVID, POTS - Postural Orthostatic Tachycardia Syndrome, Autonomic Dysfunction
About this trial
This is an interventional diagnostic trial for Long COVID focused on measuring SARS-CoV-2 infection, POTS, Orthostatic Intolerance, Long COVID, Long hauler COVID infection
Eligibility Criteria
Inclusion Criteria: Subjects will be 18 years or older, men and women. History of confirmed COVID-19 infection (positive contact and symptoms, antigen test or PCR). POTS will be defined as the presence of orthostatic tachycardia (>30 bpm) and chronic (>3 months) pre-syncopal symptoms. Post-COVID-19 POTS will be defined as the presence of orthostatic tachycardia (>30 bpm) and chronic (>3 months) pre-syncopal symptoms. Symptoms occurred within 2 months after COVID infection and persistent until enrollment in the study. Exclusion Criteria: Individuals with a history of physician diagnosed myocardial infarction, angina, heart failure, stroke, or transient ischemic attack, or who had undergone an invasive procedure for CVD (coronary artery bypass graft, angioplasty, valve replacement, pacemaker placement or other vascular surgeries). Inability to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits, and unlikelihood of completing the study. Chronic use of steroids, anti-IL6 (omalizumab), anti-TNF-alpha, other immunosuppressants. Chronic use of NSAID. Should not enroll if taking without one week prior to blood sampling. Treatment with plasmapheresis, IVIG or other immune modulator
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Other
Other
Other
Post- COVID 19 POTS patients
POTS patients
Post- COVID 19 POTS patients with Controls
Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31): In post-COVID-19 POTS (cases).
Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31):Gender, age, and BMI-matched: patients with diagnosis of POTS
Inflammatory markers IL-6,Cytokines (IL-17, and IFN-ɣ), Autonomic symptoms assessment questionnaire (COMPASS 31):Gender, age, and BMI-matched: Controls are :COVID-19 infected without sequelae